Summary of findings | Quality assessment | ||||||||||||
Study (year) | Settings | Study design | Length of study | Sample size | Grading of Hypertension | Duration of follow-up | Secondary outcomes (comorbidities) | Primary outcomes (all-cause mortality) | Hazard ratio (95% CI) | Checklists | Results | ||
Lee et al. (2020) [13] | Centers for Disease Control and Prevention (Korea) | Retrospective cohort | Jan 2020 until Mar 2020 | N = 8266 | Minimal grade 1 | 2 months | Diabetes mellitus, cancer, COPD, stroke, coronary artery disease, heart failure, chronic renal disease | N = 112 | 1.07 (0.68–1.68) | Limitations | Not serious | ||
Non-ACEi/ARB, 977 | ACEi/ARB, 7289 | Non-ACEi/ ARB, 62 | ACEi/ ARB, 50 | Inconsistency | Serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Serious | ||||||||||||
Publication Bias | Undetected | ||||||||||||
Quality | High | ||||||||||||
Li et al. (2020) [12] | Central Hospital of Wuhan (China) | Retrospective cohort | 15 Jan 2020 until 15 Mar 2020 | N = 362 | Minimal grade 1 | 2 months | Cerebrovascular disease, cardiovascular disease, diabetes, chronic kidney disease | N = 77 | 0.76 (0.44–1.33) | Limitations | Not serious | ||
Non-ACEi/ARB, 247 | ACEi/ARB, 115 | Non-ACEi/ ARB, 56 | ACEi/ ARB, 21 | Inconsistency | Not serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Not serious | ||||||||||||
Publication Bias | Undetected | ||||||||||||
Quality | High | ||||||||||||
Mehra et al. (2020) [14] | Multihospital International Registry (Asia, Europe, and North America) | Retrospective cohort | 20 Dec 2019 until 15 Mar 2020 | N = 2346 | Minimal grade 1 | n/a | Heart disease, diabetes mellitus, COPD | N = 184 | 0.24 (0.17–0.33) | Limitations | Serious | ||
Non-ACEi/ARB, 920 | ACEi/ARB, 1426 | Non-ACEi/ ARB, 130 | ACEi/ ARB, 54 | Inconsistency | Not serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Not serious | ||||||||||||
Publication bias | Undetected | ||||||||||||
Quality | High | ||||||||||||
Meng et al. (2020) [17] | Shenzhen Third People’s Hospital (China) | Retrospective cohort | 11 Jan 2020 until 23 Feb 2020 | N = 42 | Grade 2 or grade 3 hypertension according to ESC | n/a | Type 2 diabetes or coronary heart disease | N = 1 | 0.46 (0.018–12.14) | Limitations | Serious | ||
Non-ACEi/ARB, 25 | ACEi/ARB, 17 | Non-ACEi/ ARB, 1 | ACEi/ ARB, 0 | Inconsistency | Serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Not serious | ||||||||||||
Publication bias | Detected | ||||||||||||
Quality | Low | ||||||||||||
Yang et al. (2020) [20] | Hubei Provincial Hospital of Traditional Chinese Medicine (China) | Retrospective cohort | 1 Nov 2019 until 31 Dec 2019 | N = 126 | Minimal grade 1 | 3 months | Diabetes or cardiopathy | N = 13 | 0.35 (0.08–1.51) | Limitations | Not serious | ||
Non-ACEi/ARB, 83 | ACEi/ARB, 43 | Non-ACEi/ARB, 11 | ACEi/ARB, 2 | Inconsistency | Not serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Serious | ||||||||||||
Publication bias | Undetected | ||||||||||||
Quality | Moderate | ||||||||||||
Zhou et al. [18] (2020) | Wuhan Fourth Hospital, Hubei Province (China) | Retrospective cohort | 25 Jan 2020 until 20 Feb 2020 | 36 | Minimal grade 1 | 25 days | Diabetes, cerebrovascular disease, cardiovascular disease, COPD, chronic kidney disease, malignancy, rheumatoid arthritis | N = 7 | 0.14 (0.009–2.2) | Limitations | Serious | ||
Non-ACEi/ARB, 21 | ACEi/ARB, 15 | Non-ACEi/ARB, 5 | ACEi/ARB, 2 | Inconsistency | Serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Very serious | ||||||||||||
Publication bias | Detected | ||||||||||||
Quality | Low | ||||||||||||
Fosbol et al. (2020) [16] | Danish national administrative registry (Denmark) | Retrospective cohort | 22 Feb 2020 until 4 May 2020 | N = 4480 | Minimal grade 1 | End of study period (4 May 2020) | Diabetes, myocardial infarction, cancer, cerebrovascular diseases, COPD, chronic kidney diseases | N = 197 | 0.94 (0.65–1.37) | Limitations | Not serious | ||
Non-ACEi/ARB, 3585 | ACEi/ARB, 895 | Non-ACEi/ARB, 36 | ACEi/ARB, 161 | Inconsistency | Serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Not serious | ||||||||||||
Publication bias | Undetected | ||||||||||||
Quality | High | ||||||||||||
Pan et al. (2020) [21] | Renmin Hospital of Wuhan University (China) | Retrospective single-center study | 4 Jan 2020 until 14 Feb 2020 | N = 282 | Minimal grade 1 | 30 days | Diabetes, coronary heart diseases, cerebrovascular diseases, chronic liver disease, chronic kidney disease | N = 67 | 0.31 (0.1–0.89) | Limitations | Not serious | ||
Non-ACEi/ARB, 241 | ACEi/ARB, 41 | Non-ACEi/ARB, 63 | ACEi/ARB, 4 | Inconsistency | Serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Serious | ||||||||||||
Publication bias | Undetected | ||||||||||||
Quality | Moderate | ||||||||||||
Reynolds et al. (2020) [15] | New York University Langone Health (New York) | Retrospective cohort | 1 Mar 2020 until 15 Apr 2020 | N = 2005 | Minimal grade 1 | 40 days | Heart failure, myocardial infarction, diabetes, chronic kidney disease, obstructive lung disease | N = 501 | 0.97 (0.79–1.19) | Limitations | Not serious | ||
Non-ACEi/ARB, 986 | ACEi/ARB, 1019 | Non-ACEi/ARB, 249 | ACEi/ARB, 252 | Inconsistency | Serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Not serious | ||||||||||||
Publication bias | Undetected | ||||||||||||
Quality | High | ||||||||||||
Zhang et al (2020) [19] | Hubei’s Nine Hospital (China) | Retrospective cohort | 31 Dec 2019 until 7 Mar 2020 | N = 1128 | Minimal grade 1 | 1 month | Diabetes, cardiac, or renal diseases | N = 99 | 0.34 (0.14–0.83) | Limitations | Not serious | ||
Non-ACEi/ARB, 348 | ACEi/ARB, 174 | Non-ACEi/ARB, 92 | ACEi/ARB, 7 | Inconsistency | Serious | ||||||||
Indirectness | Not serious | ||||||||||||
Imprecision | Serious | ||||||||||||
Publication Bias | Undetected | ||||||||||||
Quality | Moderate |